SCHEMBL1436731

SCHEMBL1436731

COc1ccc(O)c(C(=O)NO)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 2/20 0.57
FADS1 O60427 1/20 0.57
TMPRSS4 Q9NRS4 1/20 0.57
PLAU P00749 2/20 0.56
F2 P00734 1/20 0.56
F10 P00742 1/20 0.56
PLAT P00750 1/20 0.56
NPC1 O15118 6/20 0.55
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
RAB9A P51151 5/20 0.55
MAPT P10636 5/20 0.55
HPGD P15428 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
KDM4E B2RXH2 3/20 0.55
HSD17B10 Q99714 3/20 0.55
ALDH1A1 P00352 3/20 0.55
TP53 P04637 2/20 0.55
ALOX12 P18054 2/20 0.55
LMNA P02545 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1562332 0.86 NPC1 (0.68) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL17414607 0.86 P2RX1 (0.57) P2RX1FADS1TMPRSS4PLAUF2
SCHEMBL1639160 0.84 PLAU (0.58) P2RX1FADS1TMPRSS4PLAUF2
Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL643758 0.81 CA1 (0.72) P2RX1FADS1TMPRSS4NPC1MEN1
Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL29709382 0.81 CA1 (0.72) P2RX1FADS1TMPRSS4NPC1MEN1
SCHEMBL28093168 0.81 RAB9A (0.71) P2RX1FADS1TMPRSS4NPC1MEN1
SCHEMBL7475524 0.81 CA1 (0.53) F10NPC1RAB9AMAPTHPGD
SCHEMBL29445806 0.79 ALDH1A1 (0.72) P2RX1FADS1TMPRSS4PLAUF2
SCHEMBL6856233 0.79 NPC1 (0.58) P2RX1FADS1TMPRSS4PLAUF2
SCHEMBL29431885 0.79 CA1 (0.61) NPC1MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977383-B2 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2011-07-12 US claimed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US claimed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP claimed
US-9603354-B2 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2017-03-28 US disclosed
EP-1930319-B1 Proline derivatives and use thereof as drugs MITSUBISHI TANABE PHARMA CORP (JP) 2012-05-02 EP disclosed
US-7977383-B2 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2011-07-12 US disclosed
EP-1362511-B1 Protective solution for preventing ischaemia KOEHLER CHEMIE DR FRANZ (DE) 2011-03-30 EP disclosed
EP-1859679-B1 Protective solution for preventing ischaemia damage KOEHLER CHEMIE DR FRANZ (DE) 2009-10-28 EP disclosed
EP-1308439-B1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS MITSUBISHI TANABE PHARMA CORP (JP) 2008-10-15 EP disclosed
EP-1950199-A1 Proline derivatives and use thereof as drugs Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-30 EP disclosed
EP-1930319-A1 Proline derivatives and use thereof as drugs Mitsubishi Tanabe Pharma Corporation (JP) 2008-06-11 EP disclosed
EP-1859679-A1 Protective solution for preventing ischaemia damage Dr. Franz Köhler Chemie GmbH (DE) 2007-11-28 EP disclosed
US-20060173056-A1 Proline derivatives and use thereof as drugs KITAJIMA HIROSHI 2006-08-03 US disclosed
US-7074794-B2 Proline derivatives and the use thereof as drugs MITSUBISHI PHARMA CORPORATION (JP) 2006-07-11 US disclosed
US-7060722-B2 Proline derivatives and use thereof as drugs MITSUBISHI PHARMA CORPORATION (JP) 2006-06-13 US disclosed
US-20050245538-A1 Proline derivatives and use thereof as drugs KITAJIMA HIROSHI 2005-11-03 US disclosed
US-20040106655-A1 Proline derivatives and the use thereof as drugs MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-06-03 US disclosed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US disclosed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP disclosed
EP-1308439-A1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS WELFIDE CORPORATION (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173056-A1 Proline derivatives and use thereof as drugs DPP4, DPP3, DPP7 P2RX1 360/4885FADS1 3904/4885TMPRSS4 44/4885
US-20050245538-A1 Proline derivatives and use thereof as drugs DPP4, DPP3, DPP7 P2RX1 360/4885FADS1 3904/4885TMPRSS4 44/4885
US-20040106655-A1 Proline derivatives and the use thereof as drugs DPP4, DPP3, DPP7 P2RX1 322/4885FADS1 3245/4885TMPRSS4 43/4885
US-20030215781-A1 Protective solutions for organs GLS, CA1, SI P2RX1 4251/4885FADS1 4494/4885TMPRSS4 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.